Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | APP | P05067 | 3/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17815897 | 0.82 | POLB (0.69) | POLBTGFBR1ALDH1A1 | |
| SCHEMBL26176327 | 0.81 | POLB (0.68) | POLBAPPTGFBR1ALDH1A1MAPT | |
| SCHEMBL19788243 | 0.79 | POLB (0.66) | POLBTGFBR1ALDH1A1MAPTMAPK1 | |
| SCHEMBL17812869 | 0.78 | POLB (0.64) | POLBTGFBR1ALDH1A1MAPTMAPK1 | |
| SCHEMBL7230392 | 0.73 | POLB (0.58) | POLBALDH1A1MAPTMAPK1RAB9A | |
| SCHEMBL26254579 | 0.72 | TGFBR1 (0.43) | POLBAPPTGFBR1ALDH1A1RAB9A | |
| SCHEMBL25045604 | 0.71 | CYP1A2 (0.33) | POLBAPP | |
| Ethane SCHEMBL1752493 | 0.70 | TGFBR1 (0.42) | POLBAPPTGFBR1ALDH1A1RAB9A | |
| SCHEMBL26174495 | 0.69 | POLB (0.48) | POLBTGFBR1 | |
| SCHEMBL3026036 | 0.68 | MAP3K14 (0.33) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | POLB 2137/4885APP 3011/4885TGFBR1 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.